The NCI Radiation Oncology-Biology Integration Network (ROBIN) Advances Dynamic Biology Approaches in Clinical Trials

At the third annual ROBIN investigator meeting in May 2026, oncologists, molecular biologists, and data scientists discussed ways to improve the routine uses of radiation therapy. ROBIN is an NCI-funded research network that aims to address critical gaps in radiation oncology by integrating advanced biological research, technologic innovation, and clinical practice.

The 2026 ROBIN meeting focused on decoding the effects of radiation treatment on tumor biology. Historically, the medical community has considered radiation therapy to be aimed at a static target - the tumor, but it is possible that the stress of radiation can cause a tumor to change and adapt; therefore, radiation might expose new cancer biology during treatment.

The Mid-Therapy Window

The discussions at the ROBIN meeting moved away from the traditional idea that the biological profile of a tumor is captured at two distinct moments: the initial biopsy before treatment and surgical removal or relapse after treatment. What happens to the tumor’s biology in the middle of treatment has largely remained unknown.

To address this gap, the ROBIN initiative aims to implement a concept in oncology, dynamic biology, which uses continuous, mid-therapy longitudinal sampling to map an optimal, adaptive treatment path. ROBIN aims to study radiation therapy-induced changes in tumor biology as alternative therapeutic targets by applying the features of dynamic biology.

The ROBIN investigators’ discussions revealed actionable insights stemming from a shift in clinical trial design. Their coordinated national network is systematically collecting longitudinal biological samples—tissue, blood, and imaging—not just before and after, but critically, in the middle of radiation therapy.

A Complex Analytical Engine

ROBIN’s unique collaborative structure supports its data acquisition. Five highly specialized U54 centers feed data centrally, creating a continuous, synergistic loop of innovative, shared data that complement treatment.

The multi-center interaction is already generating promising results. At the meeting, a lead investigator for one ROBIN center recounted a recent discovery on how the protein amphiregulin can mediate tumor growth following radiation. A new collaboration developed when investigators from a second ROBIN center analyzed data from another clinical trial and confirmed the results: amphiregulin can severely limit the efficacy of combined therapies.

The commitment from both the medical community and the patients to this collaborative model is noteworthy. The clinical trial staff are putting in extra time, work, and resources to support their programs, and patients on trial often consent to additional research assessments. As presented at the meeting, the network has not only met its clinical trial accrual goals—it has exceeded expectations by enrolling at 162% of its target to date (860 patients on a 530-patient goal), with the Gen-Rad trial, in particular, enrolling far beyond its planned number of patients (Figure 1).

This enrollment is feeding data into a large and complex analytical engine resulting from ROBIN’s synergistic research approach. The ROBIN centers are deploying a large "multi-omics" toolkit to analyze mid-therapy samples and generate rich, multidimensional datasets.

*Figure 1: Accrual data as of April 3, 2026, showcasing patient participation across the five national network centers.*

A Universal Framework Beyond Radiation

An important takeaway from the ROBIN meeting is that the network’s core philosophy is not tethered exclusively to radiation oncology; its impact is expected to go beyond immediate clinical trials.

ROBIN’s leaders emphasized how the network’s efforts could represent a shift in medicine. By broadening their scientific portfolios, oncologists in general, and radiation oncologists in particular, can use contemporary tools, such as single cell genomics, machine learning, and data science, to help uncover drivers of the response to radiation to potentially reduce treatment failure and provide early signals of possible toxicities. This explains why the network also focuses heavily on funding and workforce development, such as the network’s Collaborative Pilot Projects. These modestly funded projects generate preliminary data that early career scientists can leverage into larger grants from private foundations or venture capital.

While the meeting’s discussions illustrated a roadmap to help improve radiation therapy, ROBIN’s investigators also view the framework of dynamic biology as a universal concept that could be adapted broadly outside the radiation field.